Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK2 | O00142 | 2/20 | 0.47 |
| ▸ | PYGM | P11217 | 3/20 | 0.46 |
| ▸ | TYMP | P19971 | 5/20 | 0.46 |
| ▸ | CDK1 | P06493 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ALB | P02768 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18871260 | 0.90 | PYGM (0.57) | TK2PYGMTYMPCDK1 | |
| SCHEMBL40665 | 0.90 | PYGM (0.57) | TK2PYGMTYMPCDK1 | |
| SCHEMBL17210997 | 0.90 | PYGM (0.57) | TK2PYGMTYMPCDK1 | |
| SCHEMBL29754 | 0.90 | PYGM (0.57) | TK2PYGMTYMPCDK1 | |
| SCHEMBL28817 | 0.90 | PYGM (0.57) | TK2PYGMTYMPCDK1 | |
| SCHEMBL2903546 | 0.90 | PYGM (0.57) | TK2PYGMTYMPCDK1 | |
| SCHEMBL15810706 | 0.90 | PYGM (0.57) | TK2PYGMTYMPCDK1 | |
| SCHEMBL10008489 | 0.88 | TK2 (0.59) | TK2PYGMTYMPALDH1A1LMNA | |
| SCHEMBL19224122 | 0.88 | TK2 (0.59) | TK2PYGMTYMPALDH1A1LMNA | |
| SCHEMBL1071349 | 0.88 | TK2 (0.59) | TK2PYGMTYMPALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1730309-B1 | COMPOSITIONS AND METHODS FOR OPTIMIZING CLEAVAGE OF RNA BY RNASE H | IONIS PHARMACEUTICALS INC (US) | 2016-05-04 | — | — | EP | disclosed |
| US-20150011001-A1 | COMPOSITIONS AND METHODS FOR OPTIMIZING CLEAVAGE OF RNA BY RNASE H | ISIS PHARMACEUTICALS, INC. (US) | 2015-01-08 | — | — | US | disclosed |
| US-8790919-B2 | Compositions and methods for optimizing cleavage of RNA by RNase H | ISIS PHARMACEUTICALS, INC. (US) | 2014-07-29 | — | — | US | disclosed |
| EP-2700720-A2 | Compositions and methods for optimizing cleavage of RNA by RNASE H | Isis Pharmaceuticals, Inc. (US) | 2014-02-26 | — | — | EP | disclosed |
| US-20080207541-A1 | Contacting a eukaryotic cell with a mixed backbone oligonucleotide with a first region that forms a substrate for cleavage by an RNase and a second region which does not, and a transition moiety which modulates the transmission of the conformation of said second region into the first region | IONIS PHARMACEUTICALS, INC. | 2008-08-28 | — | — | US | disclosed |
| EP-1730309-A2 | COMPOSITIONS AND METHODS FOR OPTIMIZING CLEAVAGE OF RNA BY RNASE H | Isis Pharmaceuticals, Inc. (US) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005089268-A2 | COMPOSITIONS AND METHODS FOR OPTIMIZING CLEAVAGE OF RNA BY RNASE H | ISIS PHARMACEUTICALS, INC. (US) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207541-A1 | Contacting a eukaryotic cell with a mixed backbone oligonucleotide with a first region that forms a substrate for cleavage by an RNase and a second region which does not, and a transition moiety which modulates the transmission of the conformation of said second region into the first region | RNASEH1, NSUN3, RNASEL | TK2 495/4885PYGM 1689/4885TYMP 241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.